通过换用阿立哌唑逆转奥氮平所致精神分裂症患者体重增加：一例报告
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report.
作者信息
Okazaki Kosuke, Yamamuro Kazuhiko, Kishimoto Toshifumi
机构信息
Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan.
出版信息
Neuropsychiatr Dis Treat. 2017 Nov 21;13:2837-2840. doi: 10.2147/NDT.S148616. eCollection 2017.
Abstract
AIMS
Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases.
METHODS
We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine.
RESULTS
The weight gain improved after switching the medication, from 80.3 to 75.0 kg, a weight loss of 6.6%, and there was no significant worsening of psychological symptoms or other adverse effects.
CONCLUSIONS
Asenapine might be effective for treating patients with schizophrenia who experience olanzapine-induced weight gain.
摘要
目的
抗精神病药物对治疗精神分裂症有效，但非典型抗精神病药物会引起多种不良副作用，包括体重增加、高催乳素血症和锥体外系症状。此外，体重增加会增加患代谢性疾病的风险。
方法
我们通过将一名41岁精神分裂症男性患者的药物从奥氮平换成阿立哌唑，治疗了一例奥氮平引起的体重增加病例。
结果
换药后体重增加情况有所改善，从80.3千克降至75.0千克，体重减轻了6.6%，且心理症状或其他不良反应没有明显恶化。
结论
阿立哌唑可能对治疗因奥氮平引起体重增加的精神分裂症患者有效。
相似文献
1
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report.通过换用阿立哌唑逆转奥氮平所致精神分裂症患者体重增加：一例报告
Neuropsychiatr Dis Treat. 2017 Nov 21;13:2837-2840. doi: 10.2147/NDT.S148616. eCollection 2017.
2
Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.从其他抗精神病药物转换为阿塞那平的安全性和耐受性：两项随机、多中心、稳定的精神分裂症持续性阴性症状患者的研究结果汇总。
Neuropsychiatr Dis Treat. 2012;8:247-57. doi: 10.2147/NDT.S29891. Epub 2012 Jun 15.
3
Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.加拿大使用阿塞那平治疗精神分裂症的成本效益分析。
J Med Econ. 2014 Apr;17(4):296-304. doi: 10.3111/13696998.2014.897627. Epub 2014 Mar 11.
4
Asenapine for the Treatment of Psychotic Disorders.阿塞那平用于治疗精神障碍
Can J Psychiatry. 2017 Feb;62(2):123-137. doi: 10.1177/0706743716661324. Epub 2016 Aug 6.
5
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.阿塞那平与奥氮平治疗精神分裂症或分裂情感性障碍患者的长期评估。
Pharmacopsychiatry. 2010 Jun;43(4):138-46. doi: 10.1055/s-0030-1248313. Epub 2010 Mar 4.
6
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.在精神分裂症和双相情感障碍的治疗中，阿塞那平、依匹哌酮、鲁拉西酮和帕利哌酮的体重和代谢不良影响：系统评价和探索性荟萃分析。
CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000.
7
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.阿塞那平治疗成人精神分裂症急性加重期：一项以奥氮平作为活性对照的随机、双盲、固定剂量、安慰剂对照试验的结果
CNS Spectr. 2017 Aug;22(4):333-341. doi: 10.1017/S1092852916000377. Epub 2016 Nov 8.
8
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.阿塞那平对精神分裂症和双相情感障碍患者体重变化及代谢的影响。
J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.
9
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study.在一项双盲、固定剂量的延长期研究中探索阿立哌唑对成人精神分裂症患者的长期安全性。
Neuropsychiatr Dis Treat. 2017 Jul 31;13:2021-2035. doi: 10.2147/NDT.S130211. eCollection 2017.
10
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].[精神分裂症患者护理环境的成本效益分析：长效注射制剂下非典型抗精神病药物的影响]
Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5.
本文引用的文献
1
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.第二代抗精神病药物治疗精神分裂症和重度抑郁症时的激活和镇静不良反应：绝对风险增加及伤害需治数
J Clin Psychopharmacol. 2017 Apr;37(2):138-147. doi: 10.1097/JCP.0000000000000665.
2
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.英国精神药理学会关于与精神病及抗精神病药物治疗相关的体重增加、代谢紊乱和心血管风险管理的指南。
J Psychopharmacol. 2016 Aug;30(8):717-48. doi: 10.1177/0269881116645254. Epub 2016 May 4.
3
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.干预有效性临床抗精神病药物试验（CATIE）中缓解、反应和治疗持续的预后亚组。
J Clin Psychiatry. 2015 Nov;76(11):1535-45. doi: 10.4088/JCP.14m09320.
4
Antipsychotic treatment of schizophrenia: an update.抗精神病药物治疗精神分裂症：最新进展。
Asian J Psychiatr. 2014 Oct;11:3-7. doi: 10.1016/j.ajp.2014.08.002. Epub 2014 Aug 13.
5
Almost all antipsychotics result in weight gain: a meta-analysis.几乎所有抗精神病药物都会导致体重增加：一项荟萃分析。
PLoS One. 2014 Apr 24;9(4):e94112. doi: 10.1371/journal.pone.0094112. eCollection 2014.
6
Treatment by asenapine for 5 weeks decreases weight and triglycerides levels of Wistar rats.阿塞那平治疗5周可降低Wistar大鼠的体重和甘油三酯水平。
Schizophr Res. 2014 Apr;154(1-3):124-5. doi: 10.1016/j.schres.2014.02.002. Epub 2014 Feb 22.
7
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.阿塞那平对精神分裂症和双相情感障碍患者体重变化及代谢的影响。
J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.
8
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.与切换和中断使用非典型抗精神病药物相关的戒断症状和反弹综合征：理论背景和实际建议。
CNS Drugs. 2013 Jul;27(7):545-72. doi: 10.1007/s40263-013-0079-5.
9
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.15 种抗精神分裂症药物的疗效和耐受性比较：一项多治疗荟萃分析。
Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27.
10
The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers.澳大利亚西部精神疾病患者因可预防的身体疾病导致的预期寿命差距：基于人群登记的回顾性分析。
BMJ. 2013 May 21;346:f2539. doi: 10.1136/bmj.f2539.
Zotero 插件